New research conducted by Harvard scientists is laying out a road map to one of the holy grails of modern medicine: a cure for cancer. As described in a paper recently published in eLife, Martin Nowak, a professor of mathematics and of biology and director of the Program for Evolutionary Dynamics, and co-author Ivana Bozic, a postdoctoral fellow in mathematics, show that, under certain conditions, using two drugs in a “targeted therapy” – a treatment approach designed to interrupt cancer’s ability to grow and spread – could effectively cure nearly all cancers.
Source: Pharma World
UK patients with advanced prostate cancer have been given access to a new treatment that could prolong survival following the launch of Astella’s Xtandi in the country. Xtandi (enzalutamide) was licensed in Europe this month for the treatment of men with advanced prostate cancer whose disease has become resistant to first-line hormonal treatments and has progressed following docetaxel chemotherapy. The green light came on the back of key trial data showing a 37% reduction of the risk of death versus placebo for patients taking Xtandi during the study, and that the pill can give men 4.8 extra months of life on average. Xtandi’s availability has been welcomed given that up to 20% of men develop resistance to first-line hormone treatment within five years of follow up, and options remain very limited.
Source: Pharma Times
GlaxoSmithKline has met with Chinese officials to tackle the bribery scandal engulfing the firm and acknowledged that some executives have indeed been involved with illegal activities.
Abbas Hussain, GSK’s president of Europe, Japan, emerging markets and Asia Pacific, flew to China last week and has had “a very constructive meeting with the Ministry of Public Security” in the country. The latter has been looking into “serious economic crimes” and last week said bribes were generally paid through travel agencies or as “project sponsorships”. GSK is also suspected of being involved in tax-related crime, “involving a large number of people and significant amounts of money”.
In a statement sent to PharmaTimes World News, Mr Hussain said that “we are very grateful for their time”, adding that “GSK is taking this situation extremely seriously and that is why we are here”. He went on to say that “certain senior executives of GSK China who know our systems well, appear to have acted outside of our processes and controls which breaches Chinese law.
Source: Pharma Times